Capsule Filling How Pharma Packaging Meets the Rising Demand for Capsule Filling
Cipla enhances its filling capacities with a new capsule filling machine — GKF 2500 ASB 100% – The pharmaceutical industry in India is growing at a rapid pace. The shift from large medicine batches to more complex formulations has led to a high demand for sophisticated technologies. In parallel, pharmaceutical producers are expanding their export activities to North America and Europe, where they must meet stringent safety and quality regulations. Cipla, one of the largest Indian pharmaceutical manufacturing companies, has also experienced a boost in demand, and has enhanced its filling capacities with a new capsule filling machine—GKF 2500 ASB 100% from Bosch Packaging Technology.
Cipla was established in 1935 and today is one of the world’s largest generic pharmaceutical companies with a presence in over 170 countries. The company started business with the vision of making India self-reliant and self-sufficient in healthcare, and now manufactures over 2,000 products in 65 therapeutic categories and more than 40 dosage forms. These include tablets and capsules, lyophilized injections, pre-filled syringes, eye drops and other pharmaceutical liquids and APIs.
Cipla is well-known around the world for producing affordable, high-quality medicines that meet the requirements of patients across therapies. Head, Cipla–Kurkhumbh plant, Sudhir Gule points out, “India has seen a paradigm shift over the past 15 years. We now have one of the best pharmaceutical industries in the world. This has led to numerous changes and an increase in the sophistication of our formulations and exports.”
Although the figures in different industry reports vary strongly, they Indian pharmaceutical market is set for further growth. In the last decade, the country’s healthcare sector has tripled in size. While the local demand is continuously growing, the same accounts for drug exports. In fact, pharmaceutical exports from India are forecasted to increase more than twofold over the next five years. India already is a global leader in the generic drug market, and national companies are currently expanding their sales to other emerging markets, as well as the United States and Europe. “Besides that, further areas of growth are to be found in contract manufacturing and hosting clinical trials,” Gule says.
Complex formulations on the rise
The number of Indian drug manufacturers that have already started to export their products to the so called developed markets has risen at an astonishing pace. Following the demand of these markets, many companies have invested in sophisticated machinery to meet the more complex requirements.
“For instance, the demand for smaller packages has increased to make storage easier. But foremost, the regulations are very strict and we must focus on high quality to be able to compete with local providers,” Gule explains. Cipla is well-positioned to answer the demands both locally and globally. Over the past years, the company has continuously equipped its plants with new highperformance machines.
For more than ten years, Cipla has been one of Bosch’s key customers in India, and both companies look back on many successful joint projects. Cipla uses different generations and types of filling machines of the GKF series, as well as several checkweighers of the KKE series at different production sites across India. The latest successfully completed project is the installation of a new capsule filling machine at Cipla’s Kurkhumbh plant.
This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 43760664)